Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with all data for entry = 9343
TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458748(US10759766, Compound C004)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458777(US10759766, Compound C122)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458778(US10759766, Compound C124)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458766(US10759766, Compound C038)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458775(US10759766, Compound C119)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458764(US10759766, Compound C035)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458765(US10759766, Compound C036)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458761(US10759766, Compound C028)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458762(US10759766, Compound C029)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458759(US10759766, Compound C019)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458760(US10759766, Compound C022)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458755(US10759766, Compound C017)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458757(US10759766, Compound C018)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458753(US10759766, Compound C015)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458754(US10759766, Compound C016)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458751(US10759766, Compound C009)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458752(US10759766, Compound C014)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458757(US10759766, Compound C018)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458759(US10759766, Compound C019)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458753(US10759766, Compound C015)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458755(US10759766, Compound C017)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458751(US10759766, Compound C009)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458752(US10759766, Compound C014)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458776(US10759766, Compound C121)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458748(US10759766, Compound C004)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458783(US10759766, Compound C146)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458774(US10759766, Compound C109)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458767(US10759766, Compound C040)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458763(US10759766, Compound C030)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458782(US10759766, Compound C145)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458779(US10759766, Compound C134)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458780(US10759766, Compound C141)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Neupharma

US Patent
LigandPNGBDBM458781(US10759766, Compound C143)
Affinity DataIC50: 100nMAssay Description:BRAF and BRAF V600E: Inhibitory activities Inhibitory activities of compounds against BRAF, and BRAF V600E were measured by Invitrogen using Z′...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458777(US10759766, Compound C122)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458778(US10759766, Compound C124)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458775(US10759766, Compound C119)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458776(US10759766, Compound C121)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458772(US10759766, Compound C100)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458773(US10759766, Compound C102)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458769(US10759766, Compound C080)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458770(US10759766, Compound C086)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458766(US10759766, Compound C038)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458768(US10759766, Compound C053)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458764(US10759766, Compound C035)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458765(US10759766, Compound C036)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458762(US10759766, Compound C029)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458763(US10759766, Compound C030)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458760(US10759766, Compound C022)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458761(US10759766, Compound C028)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM458774(US10759766, Compound C109)
Affinity DataIC50: 100nMAssay Description:KDR (VEGFR2): Inhibitory activities of compounds against KDR (VEGFR2) were also measured by Invitrogen using Z′-LYTE Method as described above ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
US Patent

Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: